During this year we have focused on the study of kidney injury andregeneration, renal cancer and inherited rare kidney diseases (RD), taking intoaccount sex differences in disease susceptibility and progression. We have identifiedpotential biomarkers for risk assessment and prediction of outcomes, therapeutictargets and therapeutic approaches. This is especially relevant for RD with nospecific treatment or clinical assays ongoing. We also started a gene therapystrategy to treat some renal inherited diseases in collaboration with NinevahTx. Overall, our main focus is toimprove the health condition of people who suffer from a rare disease or renalcancer. We have a lasting tight collaborationwith RD patients' associations (ASDENT, DD foundation -USA-, and HIPOFAM), whogive support to our group. From these symbioses, our group has stronglypartnered the promotion of rare renal diseases and, together, we haveapproached our scientific research to the vast popular audience.

Group Leader
Anna Meseguer Navarro

Principal Investigator (PI)
Gema Ariceta, Enric Trilla Herrera, Cristina Martínez

Gerard Cantero-Recasens, Mònica Durán, Glòria Fraga, Marina Muñoz, Héctor Rios, Victor Perez, Mercedes López-González, Alejandro Cruz, Sara Chocron, David Lorente, Alonso Narváez, Luis Castro

PhD Students
Toni Cuevas, Julieta Torchia, Luis Castro, Miguel Aranda

Nursing and Technical Staff
Teresa Eixarch, José Ramón Jarrin, Mariona Asensio








Duran M, Carla Burballa C, Cantero-Recasens G, Butnaru C, Malhotra V, Ariceta G, Sarró E, Meseguer A.
Novel Dent Disease 1 cellular models reveal biological processes underlying ClC-5 loss-of-function.
Hum Mol Genet. 2021 May 13:ddab131
DOI: doi: 10.1093/hmg/ddab131.
IF: 6.15

Arévalo J, Lorente D, Trilla E, Salcedo MT, Morote J, Meseguer A
Nuclear and cytosolic pS727-STAT3 levels correlate with overall survival of patients affected by clear cell renal cell carcinoma (ccRCC).
Sci Rep. 2021 Mar 26;11(1):6957.
DOI: doi: 10.1038/s41598-021-86218-x.
IF: 4.38

Gema Ariceta, Bradley P Dixon, Seong Heon Kim, Gaurav Kapur, Teri Mauch, Stephan Ortiz, Marc Vallee , Andrew E Denker, Hee Gyung Kang, Larry A Greenbaum
The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment
Kidney Int. 2021 Jul;100(1):225-237.
DOI: doi: 10.1016/j.kint.2020.10.046
IF: 10.61

Gema Ariceta , Fadi Fakhouri , Lisa Sartz , Benjamin Miller , Vasilis Nikolaou , David Cohen , Andrew M Siedlecki , Gianluigi Ardissino
Eculizumab discontinuation in atypical haemolytic uraemic syndrome: TMA recurrence risk and renal outcomes
Clin Kidney J . 2021 Jan 24;14(9):2075-2084
DOI: doi: 10.1093/ckj/sfab005
IF: 4.45

Giralt M, Chocron S, Ferrer R, Ariceta G.
Plasma intact fibroblast growth factor 23 level is a useful tool for diagnostic approach of renal hypophosphatemia
Pediatr Nephrol. 2021 Apr;36(4):1025-1028.
DOI: doi: 10.1007/s00467-020-04906-8
IF: 3.71

Desarrollo de una terapia génica para el tratamiento de las formas genética del Síndrome Nefrótico (AAV-Crb2)
Principal Investigator: NInevah TX. Anna Meseguer (PI VHIR)
Agency: Ministerio de Economía y Competitividad. CDTI. CERVERA (IDI-20200258).
Funding: 657,130€ (308,054€ VHIR)
Period: 2020-2022

Systems biology to discover pathophysiologic mechanisms and therapeutic targets in Familial Hypomagnesemia with Hypercalciuria and Nephrocalcinosis
Principal Investigator: Gema Ariceta
Agency: Instituto de Salud Carlos III (ISCIII)
Funding: 171,820€
Period: 2018-2021 (extended until 2023)

Integrated multidisciplinary -omic approach to unravel Dent disease pathophysiological mechanisms and drug discovery for unmet therapeutic solutions
Principal Investigator: Anna Meseguer
Agency: Fundación Asdent
Funding: 180,000€
Period: 2017-2021

Principal Investigator: NInevah TX. Anna Meseguer (PI VHIR)
Agency: European Institute of Innovation and Technology (EIT). EiT Health ref 020-HS-0320
Funding: 50,000€
Period: 2020 - 2021

RedinREN 2.0
Principal Investigator: Daniel Serón; Coordinator: Anna Meseguer
Agency: Instituto de Salud Carlos III (ISCIII)
Funding: 102,300€
Period: 2017-2021

Priority Number: EP13759778.7
Priority Date: 22/05/2017
Applicants: 100% VHIR